by secretome | Oct 4, 2022 | News, Uncategorized
Secretome Therapeutics, a preclinical company developing novel therapies derived from neonatal mesenchymal stem cells, today announced the appointment of Angela Shen, M.D., M.B.A, to its Board of Directors. Dr. Shen is currently the Vice President, Strategic...
by Sudhish Sharma | Jun 17, 2022 | Journals, Uncategorized
Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...
by secretome | Jun 10, 2021 | News, Uncategorized
NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced...
by secretome | Sep 10, 2019 | News, Uncategorized
The Maryland Stem Cell Research Commission (Commission) has approved funding to its first round of fiscal year 2020 recipients for a total of $1,351,400. The Commission has also announced new leadership with the election of a new chair and vice chair to serve for the...
by Sudhish Sharma | May 22, 2019 | Journals, Uncategorized
Abstract The stem cell field is hindered by its inability to noninvasively monitor transplanted cells within the target organ in a repeatable, time-sensitive, and condition-specific manner. We hypothesized that quantifying and characterizing transplanted cell–derived...
by Sudhish Sharma | Jul 6, 2018 | Journals, Uncategorized
Abstract Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete...
